BACKGROUND: The current study was a phase 1 clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG). The trial was designed to determine the maximum tolerated dose (MTD) and toxicity of irinotecan (CPT-11) when administered with temozolomide (TMZ) and O(6)-benzylguanine (O(6)-BG). METHODS: All 3 drugs, CPT-11, TMZ, and O(6)-BG, were administered on Day 1 of a 21-day treatment. First, patients were treated with a 1-hour bolus infusion of O(6)-BG at a dose of 120 mg/m(2) followed immediately by a 48-hour continuous infusion of O(6)-BG at a dose of 30 mg/m(2)/d. Second, within 60 minutes of the end of the 1-hour bolus infusion of O(6)-BG, TMZ was administered orally at a dose of 355 mg/m(2). Third, 1 hour after administration of TMZ, CPT-11 was infused over 90 minutes. Patients were accrued to 1 of 2 strata based on CYP3A1- and CYP3A4-inducing antiepileptic drug (EIAED) use; dose escalation was conducted independently within these strata. RESULTS: Fifty-five patients were enrolled. In both strata, the dose-limiting toxicities were hematologic and included grade 4 neutropenia, febrile neutropenia, leukopenia, and/or thrombocytopenia. For Stratum 1 (EIAEDs), when TMZ was administered at a dose of 355 mg/m(2), the MTD of CPT-11 was determined to be 120 mg/m(2). In contrast, for Stratum 2 (no EIAEDs), when TMZ was administered at a dose of 200 mg/m(2), the MTD of CPT-11 was determined to be 80 mg/m(2). CONCLUSIONS: The authors believe that the results of the current study provide the foundation for a phase 2 trial of O(6)-BG in combination with CPT-11 and TMZ in patients with MG.
BACKGROUND: The current study was a phase 1 clinical trial conducted with patients who had recurrent or progressive malignant glioma (MG). The trial was designed to determine the maximum tolerated dose (MTD) and toxicity of irinotecan (CPT-11) when administered with temozolomide (TMZ) and O(6)-benzylguanine (O(6)-BG). METHODS: All 3 drugs, CPT-11, TMZ, and O(6)-BG, were administered on Day 1 of a 21-day treatment. First, patients were treated with a 1-hour bolus infusion of O(6)-BG at a dose of 120 mg/m(2) followed immediately by a 48-hour continuous infusion of O(6)-BG at a dose of 30 mg/m(2)/d. Second, within 60 minutes of the end of the 1-hour bolus infusion of O(6)-BG, TMZ was administered orally at a dose of 355 mg/m(2). Third, 1 hour after administration of TMZ, CPT-11 was infused over 90 minutes. Patients were accrued to 1 of 2 strata based on CYP3A1- and CYP3A4-inducing antiepileptic drug (EIAED) use; dose escalation was conducted independently within these strata. RESULTS: Fifty-five patients were enrolled. In both strata, the dose-limiting toxicities were hematologic and included grade 4 neutropenia, febrile neutropenia, leukopenia, and/or thrombocytopenia. For Stratum 1 (EIAEDs), when TMZ was administered at a dose of 355 mg/m(2), the MTD of CPT-11 was determined to be 120 mg/m(2). In contrast, for Stratum 2 (no EIAEDs), when TMZ was administered at a dose of 200 mg/m(2), the MTD of CPT-11 was determined to be 80 mg/m(2). CONCLUSIONS: The authors believe that the results of the current study provide the foundation for a phase 2 trial of O(6)-BG in combination with CPT-11 and TMZ in patients with MG.
Authors: P Pourquier; J L Waltman; Y Urasaki; N A Loktionova; A E Pegg; J L Nitiss; Y Pommier Journal: Cancer Res Date: 2001-01-01 Impact factor: 12.701
Authors: Henry S Friedman; Stephen Keir; Anthony E Pegg; Peter J Houghton; O Michael Colvin; Robert C Moschel; Darell D Bigner; M Eileen Dolan Journal: Mol Cancer Ther Date: 2002-09 Impact factor: 6.261
Authors: Christopher D Turner; Sridharan Gururangan; James Eastwood; Krystal Bottom; Melody Watral; Rodney Beason; Roger E McLendon; Allan H Friedman; Sandra Tourt-Uhlig; Langdon L Miller; Henry S Friedman Journal: Neuro Oncol Date: 2002-04 Impact factor: 12.300
Authors: V J Patel; G B Elion; P J Houghton; S Keir; A E Pegg; S P Johnson; M E Dolan; D D Bigner; H S Friedman Journal: Clin Cancer Res Date: 2000-10 Impact factor: 12.531
Authors: W K Yung; M D Prados; R Yaya-Tur; S S Rosenfeld; M Brada; H S Friedman; R Albright; J Olson; S M Chang; A M O'Neill; A H Friedman; J Bruner; N Yue; M Dugan; S Zaknoen; V A Levin Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Timothy F Cloughesy; Emese Filka; John Kuhn; Gillian Nelson; Fairooz Kabbinavar; Henry Friedman; Langdon L Miller; Gary L Elfring Journal: Cancer Date: 2003-05-01 Impact factor: 6.860
Authors: E Raymond; M Fabbro; V Boige; O Rixe; M Frenay; G Vassal; S Faivre; E Sicard; C Germa; J M Rodier; L Vernillet; J P Armand Journal: Ann Oncol Date: 2003-04 Impact factor: 32.976
Authors: Mark R Gilbert; Jeffrey G Supko; Tracy Batchelor; Glenn Lesser; Joy D Fisher; Steven Piantadosi; Stuart Grossman Journal: Clin Cancer Res Date: 2003-08-01 Impact factor: 12.531
Authors: W K Yung; R E Albright; J Olson; R Fredericks; K Fink; M D Prados; M Brada; A Spence; R J Hohl; W Shapiro; M Glantz; H Greenberg; R G Selker; N A Vick; R Rampling; H Friedman; P Phillips; J Bruner; N Yue; D Osoba; S Zaknoen; V A Levin Journal: Br J Cancer Date: 2000-09 Impact factor: 7.640
Authors: W Cai; N V Maldonado; W Cui; N Harutyunyan; L Ji; R Sposto; C P Reynolds; N Keshelava Journal: Br J Cancer Date: 2010-10-05 Impact factor: 7.640
Authors: Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Allan H Friedman; John H Sampson; Roger E McLendon; James E Herndon; Henry S Friedman Journal: J Neurooncol Date: 2009-06-17 Impact factor: 4.130
Authors: Chen Farhy; Santosh Hariharan; Jarkko Ylanko; Luis Orozco; Fu-Yue Zeng; Ian Pass; Fernando Ugarte; E Camilla Forsberg; Chun-Teng Huang; David W Andrews; Alexey V Terskikh Journal: Elife Date: 2019-10-22 Impact factor: 8.140